Quotables
"We live in a society exquisitely dependent on science and technology, in which hardly anyone knows anything about science and technology."
Carl Sagan
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187634 | Process for the preparation of sevelamer hydrochloride and formulation thereof Disclosed herein is an improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4 mmol/g. Further, the invention discloses Sevelamer hydrochloride compositions and a novel process for preparation of said compositions ... | 05/29/2012 |
| 8187635 | Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in com... | 05/29/2012 |
| 8124587 | 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa 2-(Aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of coagulation factor Xa are provided. The compounds are suitable for the treatment and prophylaxis of cardiovascular and thrombotic events. ... | 02/28/2012 |
| 8110219 | Controlled release dosage forms The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking fu... | 02/07/2012 |
| 8105627 | Extended release venlafaxine tablet formulation An extended release formulation for administration of venlafaxine in an oral tablet dosage form. The formulation preferably features a core, over which an outer coating is layered. The core preferably contains venlafaxine, a filler, and a water soluble cellulosic po... | 01/31/2012 |
| 7943172 | Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound, preferably imatinib or a pharmaceutically acceptable salt of imatini... | 05/17/2011 |
| 7931915 | Extended release venlafaxine formulation A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet. ... | 04/26/2011 |
| 7923028 | High dose oral formulation of bisphosphonate and a process for making thereof The invention relates to a high dose oral formulation of bisphosphonates and to a process for the preparation of such formulations. ... | 04/12/2011 |
| 7867516 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.... | 01/11/2011 |
| 7645460 | Dosage forms of risedronate Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide ... | 01/12/2010 |
| 7645459 | Dosage forms of bisphosphonates Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastroi... | 01/12/2010 |
| 7553500 | Pharmaceutical composition having uniform drug distribution and potency Pharmaceutical compositions having uniform drug distribution and potency utilizing laxofoxifene as an active ingredient and containing a silicon dioxide to reduce loss of the active ingredient during the manufacturing process and methods for manufacturing such compo... | 06/30/2009 |
| 7470435 | Extended release venlafaxine formulation A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet. ... | 12/30/2008 |
| 7435715 | Microcapsules Microcapsules for use in liquid detergents having a core and a polyelectrolyte complex shell in the form of a semipermeable membrane capable of withstanding a force before bursting of from about 20 mN to about 20,00 N and having a density of from about 900 Kg/m... | 10/14/2008 |
| 7431943 | Controlled release and taste masking oral pharmaceutical compositions Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrop... | 10/07/2008 |
| 7431944 | Delivery of multiple doses of medications Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release ... | 10/07/2008 |
| 7416738 | Modified release dosage form A modified release dosage form comprising at least one active ingredient and at least two cores surrounded by a shell is provided. The shell comprises at least one opening and provides for modified release of active ingredient upon contacting of the dosage form with... | 08/26/2008 |
| 7404970 | Pain relief composition, method to form same, and method to use same An oral dosage form which includes a bi-layer tablet consisting of an Actives Granulation layer and an Osmagen Granulation layer is disclosed. An encapsulant is disposed over that bi-layer tablet. The encapsulated bi-layer tablet includes an orally therapeutically e... | 07/29/2008 |
| 7387791 | Liposome drug delivery This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal trac... | 06/17/2008 |
| 7357946 | Uses for cellulose-containing aggregates Aggregates of cellulose-containing particles, such as particles of waste paper and optional other vegetation or waste particles are used as a carrier for additives such as insecticides, herbicides, fertilizers and nutrients. The particles can be also used as a carri... | 04/15/2008 |
| 7357945 | Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof Provided are formulations of a stable paroxetine hydrochloride tablet comprising paroxetine hydrochloride, povidone or copovidone as a binder, and an HCl free/non-hygroscopic filler, prepared by the wet granulation method. Preferably, the paroxetine hydrochloride is... | 04/15/2008 |
| 7351429 | Oral solid preparation The invention is to provide an oral solid pharmaceutical that is uniform in the content of KRP-197, having bladder-selective anticholinergic activity, being a therapeutic drug for pollakiuria and urinary incontinence, and being active with a very low dosage, that ca... | 04/01/2008 |
| 7341742 | Simethicone containing tablet composition and method A process and pharmaceutical composition containing simethicone and magnesium carbonate allows a higher production rate of simethicone containing tablets and a more consistent end product tablet. The magnesium carbonate prevents sticking of simethicone to tablet com... | 03/11/2008 |
| 7332183 | Multilayer dosage forms containing NSAIDs and triptans The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independent... | 02/19/2008 |
| 7316819 | Oral peptide pharmaceutical dosage form and method of production A pharmaceutical composition for oral delivery of a peptide is in the form of a lamination having at least two layers. The first layer of the lamination includes at least one pharmaceutically acceptable pH-lowering agent. The second layer includes a therapeutically ... | 01/08/2008 |
| 7316818 | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, a... | 01/08/2008 |
| 7303768 | Preparation of aqueous clear solution dosage forms with bile acids Compositions for pharmaceutical and other uses comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over selected ranges of pH values of the aqueous solution and methods of making such solutions. The compositions of the inve... | 12/04/2007 |
| 7303763 | Compositions for conjugated estrogens and associated methods Oral conjugated estrogen formulations are disclosed and described. In one aspect, the oral formulation may be a tablet having a core and one or more coatings thereon. In addition to conjugated estrogen ingredients, the core may include one or more organic excipients... | 12/04/2007 |
| 7303761 | Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin The present invention is related to a solid pharmaceutical composition comprising two separate regions, a first region comprising at least one non-steroidal anti-inflammatory drug (NSAID) and an adequate pharmaceutical carrier cont... | 12/04/2007 |
| 7282221 | Antiviral product, use and formulation thereof An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosag... | 10/16/2007 |
| 7276252 | Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings, shells, and combinations thereof, which provides protection to and isol... | 10/02/2007 |
| 7276253 | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof The invention relates to a stable medicament for oral administration which comprises (a) a core which contains an active ingredient selected from Omeprazole, Lansoprazole and Pantoprazole, together with customary pharmaceutical adjuvants, (... | 10/02/2007 |
| 7270831 | Orally administrable opioid formulations having extended duration of effect Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains ... | 09/18/2007 |
| 7258872 | Chromone enteric release formulation Orally administered chromones have been found to be effective in the treatment of allergic conditions such as asthma, general food allergies, ulcerative colitis, atopic eczema, chronic urticaria, and irritable bowel syndrome if it is presented such that the respecti... | 08/21/2007 |
| 7235253 | Powder containing physiologically active peptide A method is disclosed for stabilizing a physiologically active peptide in a process of preparing a powder containing the physiologically active peptide by drying an aqueous liquid containing the physiologically active peptide, wherein the method comprises adding to ... | 06/26/2007 |
| 7229643 | Oral 2-methyl-thieno-benzodiazepine formulation The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation. ... | 06/12/2007 |
| 7229640 | Paroxetine controlled release compositions A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine. ... | 06/12/2007 |
| 7220430 | Sustained-release preparation and process for producing the same The present invention is to provide a sustained release preparation comprising a drug-containing core substance and a multilayered coating layer covering the core substance, wherein all adjacent layers in the multilayered coating layer contain mutually different hyd... | 05/22/2007 |
| 7217429 | Tableted oral pharmaceutical dosage form, with enteric coating, containing a compound of benzimidazole labile in an acid medium The pharmaceutical dosage form consists of a plurality of units containing a benzimidazole compound labile in an acid medium as the active principle, each unit being comprised of an inert core, a layer containing the active principle and an intermediate layer. These... | 05/15/2007 |
| 7217431 | Controlled agglomeration A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a th... | 05/15/2007 |
